

**For Immediate Release**  
**Alembic Pharmaceuticals Limited**  
**Consolidated Results for Quarter ended 30.09.2014**

**Revenues up by 13% at Rs 548.8 crores**  
**PAT up by 25% at Rs 77.3 crores**

**Editors Synopsis**

- **Net sales up by 13% to Rs 548.8 crores against Rs 487.7 crores in the corresponding quarter last year**
- **Profit before tax up by 19% to Rs 95.7 crores against Rs 80.5 crores in the corresponding quarter last year**
- **Net profit after tax up by 25% to Rs 77.3 crores against Rs 61.6 crores in the corresponding quarter last year**
- **EBITDA margins is 19.7% at Rs 108.3 crores against 19% at Rs 92.7 crores in the corresponding quarter last year**
- **India Branded formulations sales up 18% for the quarter at Rs 275.5 crores against Rs 234.1 crores in corresponding quarter last year.**
- **International Generic Formulations sales up 9% for the quarter at Rs 123.4 crores against Rs 113.7 crores in corresponding quarter last year**
- **Net sales up by 14% for H1 to Rs 1044.9 crores against Rs 916.5 crores in the corresponding H1 last year**
- **Profit before tax up by 28% for H1 to Rs 180.6 crores against Rs 141 crores in the corresponding H1 last year**
- **Net profit after tax up by 31% for H1 to Rs 141.9 crores against Rs 108.3 crores in the corresponding H1 last year**
- **EBITDA margins is 19.6% at Rs 204.9 crores for H1 against 17.9% at Rs 164.2 crores in the corresponding H1 last year**

**Vadodara, 20<sup>th</sup> October, 2014**

Alembic Pharmaceuticals Limited reported a 13% increase in revenues to Rs 548.8 crores for the quarter ended 30<sup>th</sup> September 2014, compared to Rs 487.7 crores in the corresponding quarter last year.

The Company posted 19% growth in profit before tax at Rs. 95.7 crores for the quarter ended 30<sup>th</sup> September 2014 against Rs 80.5 crores posted in corresponding quarter last fiscal.

The net profit grew by 25% at Rs 77.3 crores for the quarter ended 30<sup>th</sup> September 2014 against Rs 61.6 crores in corresponding quarter last fiscal.

EBITDA margins for quarter ended 30<sup>th</sup> September 2014 up at 19.7% to Rs 108.3 crores from 19% at Rs 92.7 crores for corresponding quarter last year.

The company also reported 14% increase in revenue for first half of operations to Rs 1044.9 crores against Rs 916.5 crores corresponding first half last year.

The company also posted 28% growth in profit before tax at Rs 180.6 crores for first half against Rs 141 crores for corresponding first half last year. The Company also reported 31% growth in net profit for first half at Rs 141.9 crores against Rs 108.3 crores in corresponding first half last year.

### **India Branded Formulations Business**

The India Branded formulations business posted sales of Rs 275.5 crores against Rs 234.1 crores with a 18% growth over the corresponding quarter of the previous year.

Specialty and Acute segments grew by 18% and 17% respectively in current quarter.

### **International Generics**

International Generic Formulation posted growth of 9% and posted sales of Rs 123.4 crores against Rs 113.7 crores over the corresponding quarter last year.

During the quarter 1 ANDA application and for the H1 4 ANDA applications were filed taking cumulative ANDA filings of the Company to 65. During the quarter 2 DMF applications were filed taking cumulative DMF filings of the Company to 68.

Summary of Total Revenue is as under:

(Rs in Lacs)

Particulars	Q2 FY15	Q2 FY14	% Change	H1 FY15	H1 FY14	% Change
<b>Formulation</b>						
India Branded	27551	23409	18%	49879	42606	17%
India Generics	3222	3681	(-)12%	5744	6326	(-)9%
International Branded	1836	1831	-	4104	3332	23%
International Generics	12344	11367	9%	23725	19914	19%
<b>API</b>	9364	7820	20%	19995	18517	8%
<b>Export Incentives</b>	558	659	-	1041	950	-
<b>Total</b>	<b>54875</b>	<b>48767</b>	<b>13%</b>	<b>104488</b>	<b>91645</b>	<b>14%</b>

The Profit break-up is as under:

(Rs in Lacs)

Particulars	Q2 FY15	Q2 FY14	% Change	H1 FY15	H1 FY14	% Change
EBITDA	10826	9271	17%	20493	16419	25%
Profit Before Tax	9569	8049	19%	18062	14099	28%
Net Profit after Tax	7727	6164	25%	14194	10828	31%

### About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities all over the world including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through

a marketing team of over 4400 are well recognized by doctors and patients.

Information about the company can be found at [www.alembic-india.com](http://www.alembic-india.com); (reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

**For more information contact:**

**Alembic Pharmaceuticals Limited**

**Ajay Kumar Desai**

**Phone: +91 22 – 306 11681**

**Email: [ajay.desai@alembic.co.in](mailto:ajay.desai@alembic.co.in)**

**Mitanshu Shah**

**Phone: +91 265 – 3007630**

**Email: [mitanshu.shah@alembic.co.in](mailto:mitanshu.shah@alembic.co.in)**